Meera Subramaniam
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Meera Subramaniam.
Journal of Leukocyte Biology | 2010
Umakanth Khatwa; Bjoern E. Kleibrink; Steven D. Shapiro; Meera Subramaniam
Increased levels of MMP‐8 (neutrophil collagenase) have been reported in OB, but the biological role of MMP‐8 in OB is not known. MMP‐8 is an interstitial collagenase highly expressed by polymorphonuclear leukocytes, which are prominent in early OB. Here, we show that MMP‐8 promotes migration of PMNs through the collagen‐rich matrix in a mouse heterotopic airway transplant model of OB. Overall, MMP‐8−/− mice had significantly fewer PMNs in the airway lumen 2 and 14 days post‐transplantation, and the percentage of PMNs traversing the matrix to the lumen was decreased markedly in the MMP‐8−/− compared with WT mice at 14 days. There were significantly more PMNs outside of the lumen in the ECM in the MMP‐8−/− mice compared with WT mice. In vitro, significantly fewer MMP‐8−/− PMNs migrated through 3D cross‐linked collagen gels than WT PMNs. MMP inhibitor GM6001 was also able to impede migration of WT PMNs through collagen gels. The decreased migration was likely a result of pericollagenase activity of MMP‐8, as WT PMNs expressing MMP‐8 were not able to migrate effectively through collagen that was resistant to the collagenase. Protection from OB was seen in the MMP‐8−/− mice, as the airway lumen had significantly less obliteration and collagen deposition, suggesting that MMP‐8 plays an important role in the pathogenesis of OB.
Endocrine Pathology | 2004
Mary E. Sunday; Lin Shan; Meera Subramaniam
Pulmonary neuroendocrine (NE) cells are believed to be the precursor of NE lung carcinomas, including well-differentiated (carcinoids) and moderately/poorly differentiated (atypical carcinoids and small-cell carcinomas, SCLCs) subtypes. In early studies, we determined mechanisms by which NE cell-derived peptides such as bombesin-like peptide (BLP) promote normal fetal lung development. Postnatally, BLP may normally regulate perinatal adaptation of the pulmonary circulation. However, elevated BLP levels in premature infants shortly after birth predict which infants are at high risk for developing bronchopulmonary dysplasia (BPD, chronic lung disease of newborns). An anti-BLP blocking antibody abrogates clinical and pathological evidence of lung injury in two baboon models of BPD. These observations indicate that BLP mediates lung injury in BPD, supporting a role for BLP as pro-inflammatory cytokines. We have directly tested the effects of BLP on eliciting inflammatory cell infiltrates in vivo. Surprisingly, mast cells are the major responding cell population. These data suggest that the diffuse NE system may be a newly recognized component of innate immunity in multiple organ systems. We speculate that overproduction of NE cell-derived peptides such as BLP may be responsible for a variety of chronic inflammatory disorders.
Developmental Dynamics | 2008
Lin Shan; Meera Subramaniam; Rodica L. Emanuel; Simone Degan; Pamela Johnston; Denise Tefft; David Warburton; Mary E. Sunday
Murine lung development begins at embryonic day (E) 9.5. Normal lung structure and function depend on the patterns of localization of differentiated cells. Pulmonary mesenchymal cell lineages have been relatively unexplored. Importantly, there has been no prior evidence of clonality of any lung cells. Herein we use a definitive genetic approach to demonstrate a common origin for proximal and distal pulmonary mesenchymal cells. A retroviral library with 3,400 unique inserts was microinjected into the airway lumen of E11.5 lung buds. After 7–11 days of culture, buds were stained for placental alkaline phosphatase (PLAP). Most PLAP+ cells are peribronchial smooth muscle cells, initially localized laterally near the hilum, then migrating down airways to the subpleural region. Laser‐capture microdissection and polymerase chain reaction confirm the clonal identities of PLAP+ cells proximally and distally. Our observation of this fundamental process during lung development opens new avenues for investigation of maladaptive mesenchymal responses in lung diseases. Developmental Dynamics 237:750–757, 2008.
Experimental Lung Research | 2011
Olin D. Liang; Bjoern E. Kleibrink; Katharina Schuette-Nuetgen; Umakanth U. Khatwa; Bechara Mfarrej; Meera Subramaniam
ABSTRACT Lung transplantation has the worst outcome compared to all solid organ transplants due to chronic rejection known as obliterative bronchiolitis (OB). Pathogenesis of OB is a complex interplay of alloimmune-dependent and -independent factors, which leads to the development of inflammation, fibrosis, and airway obliteration that have been resistant to therapy. The alloimmune-independent inflammatory pathway has been the recent focus in the pathogenesis of rejection, suggesting that targeting this may offer therapeutic benefits. As a potent anti-inflammatory agent, epigallo-catechin-galleate (EGCG), a green tea catechin, has been very effective in ameliorating inflammation in a variety of diseases, providing the rationale for its use in this study in a murine heterotopic tracheal allograft model of OB. Mice treated with EGCG had reduced inflammation, with significantly less neutrophil and macrophage infiltration and significantly reduced fibrosis. On further investigation into the mechanisms, inflammatory cytokines keratinocyte (KC), interleukin-17 (IL-17), and tumor necrosis factor-α (TNF-α), involved in neutrophil recruitment, were reduced in the EGCG-treated mice. In addition, monocyte chemokine monocyte chemoattractant protein-1 (MCP-1) was significantly reduced by EGCG treatment. Antifibrotic cytokine interferon-γ–inducible protein-10 (IP-10) was increased and profibrotic cytokine transforming growth factor-β (TGF-β) was reduced, further characterizing the antifibrotic effects of EGCG. These findings suggest that EGCG has great potential in ameliorating the development of obliterative airway disease.
Stem Cells International | 2014
Alicia Casey; Fabian Dirks; Olin D. Liang; Hakima Harrach; Katharina Schuette-Nuetgen; Kristen T. Leeman; Carla F. Kim; Craig Gerard; Meera Subramaniam
Obliterative bronchiolitis (OB) remains the most significant cause of death in long-term survival of lung transplantation. Using an established murine heterotopic tracheal allograft model, the effects of different routes of administration of bone marrow-derived multipotent stromal cells (MSCs) on the development of OB were evaluated. Tracheas from BALB/c mice were implanted into the subcutaneous tissue of major histocompatibility complex- (MHC-) disparate C57BL/6 mice. At the time of transplant, bone marrow-derived MSCs were administered either systemically or locally or via a combination of the two routes. The allografts were explanted at various time points after transplantation and were evaluated for epithelial integrity, inflammatory cell infiltration, fibrosis, and luminal obliteration. We found that the most effective route of bone marrow-derived MSC administration is the combination of systemic and local delivery. Treatment of recipient mice with MSCs suppressed neutrophil, macrophage, and T-cell infiltration and reduced fibrosis. These beneficial effects were observed despite lack of significant MSC epithelial engraftment or new epithelial cell generation. Our study suggests that optimal combination of systemic and local delivery of MSCs may ameliorate the development of obliterative airway disease through modulation of immune response.
Pediatric Pulmonology | 2014
Rizwana Popatia; Meera Subramaniam
Dysautonomia such as POTS syndrome presenting with respiratory symptoms can often be misdiagnosed for other common pulmonary conditions. It can be diagnosed with a comprehensive history and orthostatic vital measurement. Simple diagnostic test such as diffusing capacity in supine and standing position can emerge as a noninvasive tool to guide the long‐term monitoring and treatment response. Pediatr Pulmonol. 2014; 49:E25–E26.
Blood | 1996
Meera Subramaniam; Paul S. Frenette; Simin Saffaripour; Robert C. Johnson; Richard O. Hynes; Denisa D. Wagner
Journal of Experimental Medicine | 1995
Meera Subramaniam; Simin Saffaripour; S. R. Watson; Tanya N. Mayadas; Richard O. Hynes; Denisa D. Wagner
Blood | 1995
Robert C. Johnson; Tanya N. Mayadas; Paul S. Frenette; Mebius Re; Meera Subramaniam; Ann S. LaCasce; Richard O. Hynes; Denisa D. Wagner
American Journal of Respiratory and Critical Care Medicine | 2003
Ling Yi L Chang; Meera Subramaniam; Bradley A. Yoder; Brian J. Day; Misoo C. Ellison; Mary E. Sunday; James D. Crapo